Novel bispecific T-cell receptor therapy shows early promise in advanced solid tumors
Source: Healio, September 2022
An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.
Treatment with IMC-F106C produced durable responses or disease stabilization in most patients and appeared well-tolerated, the researchers noted.
Background
IMC-F106C (Immunocore) is an investigational bispecific fusion protein comprising a soluble T-cell receptor that targets HLA-A*02:01 PRAME-derived peptides and an anti-CD3 chain that binds to and activates a patient’s endogenous T cells.